The Cystinosis Research Network (CRN) has created a new program to bring light to cystinosis families during these uncertain times. It is called the Brighter Days Care Package Program. Brighter…
Would you be shocked to find out that before Evrysdi, there were zero orally-administered drugs approved to treat patients with spinal muscular atrophy (SMA)? But now, things have changed. Last week,…
Nobody knows the exact cause of Parkinson's disease. However, many researchers believe that environmental triggers may play a factor. Now, the Michael J. Fox Foundation (MJFF) is encouraging American…
Happy Friday! We're about halfway through Stevens-Johnson Syndrome Awareness Month. It's a type of severe skin reaction that often involves admission to a burn unit for treatment. Looking for ways…
Finding the best care for every cancer patient can be difficult, as every patient has different needs. Precision care aims to provide the best treatment for every patient, meaning that…
Recently, Daiichi Sankyo and AstraZeneca announced a clinical trial collaboration to determine whether using a combination of TAGRISSO (osimertinib) and patritumab deruxtecan (U3-1402) would be effective in treating patients…
Researchers created a new free-movement pattern (FMP) Y-maze from a Y-maze behavioral test that already exists. They believe the test will be effective in people and in animal models. Their…
According to a story from GlobeNewswire, the drug development company Corbus Pharmaceuticals Holdings, Inc., has recently announced that it has completed its enrollment of patients for an upcoming phase 3…
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
